|
|
Home | Investor Relations | 10-K |
|
|
|
|
|
 |
 |
 |
 |
 |
|
|
 The Company’s International Technidyne Corporation (ITC) subsidiary, which supplies point-of-care coagulation, blood gas, electrolyte and chemistry test systems, as well as skin incision products, continues to achieve record sales growth while providing Thoratec a broader product line to address the cardiovascular marketplace. The outlook for continued growth at ITC is promising as we look for additional contributions from its new offerings, including the IRMA TRUpoint product line acquired during the year. The addition of IRMA TRUpoint to ITC’s hospital point-of-care product line gives ITC the most complete line of coagulation and critical care testing for bedside point-of-care applications. ITC’s ProTime System, which measures prothrombin time to monitor warfarin therapy, made strong headway in the professional market and is starting to gain traction in the self-testing market, which is now eligible for Medicare reimbursement. HEMOCHRON Signature systems are used for point-of-care coagulation testing, and are gaining increased market penetration throughout the hospital and pharmaceutical clinical trial markets. Sales from ITC’s new product offerings were encouraging. The Hgb Pro, an alternate site testing instrument for measuring hemoglobin in the blood system, has benefited from a joint marketing program with a major pharmaceutical company and the support of the industry’s leading distributors. The Response RxDx, which measures heparin and protamine dosing requirements during cardiac bypass surgery, gained market share. Future products from ITC will combine traditional ITC HEMOCHRON and IRMA TRUpoint technology. Other product offerings anticipated during the year include a new IRMA TRUpoint cartridge for creatine testing and an advanced HEMOCHRON Signature system with increased functionality.
|
